Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co LtdfiledCriticalEisai R&D Man Co Ltd
Publication of MY142761ApublicationCriticalpatent/MY142761A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
THE PRESENT INVENTION PROVIDES A METHOD PREVENTING OR TREATING A DISEASE CAUSED BY OXIDATION IN VIVO BY ADMINISTERING A PHARMACOLOGICALLY EFFECTIVE AMOUNT OF A LEAST ONE COMPOUND SELECTED FROM THE GROUP CONSISTING OF :(1) 2,5,7.8 - TETRAMETHYL - 2 (CARBOXYETHYL) - 6 - HYDROXYCHROMANE ; AND @(2) 2,7.8 - TRIMETHYL - 2 - (B - CARBOXYETHYL) - 6 - HYDROXYCHROMANE.@FURTHER, IT PROVIDES USE OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF (3) X - TOCOPHEROL, (4) X-TOCOTRIENOL, (5)Y - TOCOPHEROL AND (6) Y - TOCOTRIENOL FOR GENERATION IN VIVO OF ANY OF THE ABOVE COMPOUNDS (1) AND (2) TO TREAT A DISEASE CAUSED BY OXIDATED LOW DENSITY LIPOPROTEIN (LDL).@AS THE ABOVE - MENTIONED DISEASE, ARTERIOSCLEROSIS IS PARTICULARLY PREFERRED.
MYPI200144802000-09-272001-09-25The use of gamma-cehc as antioxidants
MY142761A
(en)
Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject